Related Experiment Video
Updated: Mar 2, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Highlights on immune checkpoint inhibitors in non-small cell lung cancer
Meng Shen1,2,3, Xiubao Ren2,3,4
11 Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Abstract:
The treatment of advanced or refractory non-small cell lung cancer has been historically difficult owing to the lack of studies on effective systemic cure. The progress in lung cancer treatment has plateaued, necessitating new options for additional benefits. Immune checkpoint proteins are co-inhibitory factors that can diminish the antigen-specific immune responses by attenuating the regulatory role of cytotoxic T-lymphocyte-associated protein 4, programmed cell death-1, lymphocyte-activation gene 3, and T-cell immunoglobulin mucin-3. The therapeutic strategies targeting immune checkpoints mainly focus on the monoclonal antibody of these regulatory factors, which may facilitate clinical decision making. An enhanced understanding of the drug-resistance mechanisms and the therapeutic efficacy regulation will provide opportunities to improve the clinical outcomes of non-small cell lung cancer patients. Preclinical and clinical trials on these key immune-regulatory agents, which has heralded a new era in immuno-oncology in non-small cell lung cancer treatment, are currently in development.
Insights
New immuno-oncology treatments targeting immune checkpoints like CTLA-4 and PD-1 offer hope for advanced non-small cell lung cancer. Understanding resistance mechanisms is key to improving patient outcomes.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Advanced or refractory non-small cell lung cancer (NSCLC) treatment remains challenging.
- Progress in NSCLC treatment has plateaued, requiring novel therapeutic approaches.
- Immune checkpoint proteins (e.g., CTLA-4, PD-1, LAG-3, TIM-3) suppress anti-tumor immune responses.
Purpose of the Study:
- To review current therapeutic strategies targeting immune checkpoints in NSCLC.
- To highlight the role of monoclonal antibodies in immune checkpoint inhibition.
- To emphasize the need for understanding drug resistance and efficacy regulation.
Main Methods:
- Review of preclinical and clinical trials on immune checkpoint inhibitors.
- Analysis of mechanisms of immune checkpoint protein regulation.
- Exploration of therapeutic strategies involving monoclonal antibodies.
Main Results:
- Immune checkpoint inhibitors represent a new era in NSCLC immuno-oncology.
- Targeting co-inhibitory factors like CTLA-4, PD-1, LAG-3, and TIM-3 shows therapeutic potential.
- Monoclonal antibody-based therapies are a primary strategy.
Conclusions:
- Enhanced understanding of resistance mechanisms and efficacy regulation is crucial.
- Further development of immune-regulatory agents is needed to improve NSCLC patient outcomes.
- Immuno-oncology offers promising avenues for advanced and refractory NSCLC.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...